title: Combination of rubidazone and cytosine arabinoside in the treatment of first relapse in acute myelocytic leukemia.
abstract: This study tested the efficacy of rubidazone and cytosine arabinoside in 35 patients (13 children and 22 adults) with acute myelocytic leukemia in first relapse. Induction consisted of 1-2 courses of rubidazone 200 mg/m2 days x 4 days plus cytosine arabinoside 100 mg/m2 x 7 days in CI followed by 2 consolidation courses of 3 days and 5 days. Nineteen patients (54%) achieved complete remission, 8 failed to respond, and 8 died. Twelve patients relapsed after 1 to 9 months, at a median of 4 months, 1 patient died of cardiac failure and 1 remains in complete remission at 12 months. Five patients underwent bone marrow transplantation, 3 of them autologous, 1 was still in complete remission at 29 months, 1 relapsed, and 1 died of sepsis. Two received allogeneic marrow transplants and died at 3 and 4 months afterwards of VOD and graft failure. The main toxicity was severe and prolonged myelosuppression.
authors.affiliation: Instituto de Investigaciones Hematológicas Mariono R. Castex, Buenos Aires, Argentina.
authors.forename: S
authors.initials: S
authors.lastname: Pavlovsky
authors.forename: I
authors.initials: I
authors.lastname: Fernández
authors.forename: V
authors.initials: V
authors.lastname: Palau
authors.forename: M T
authors.initials: MT
authors.lastname: Santarelli
authors.forename: R
authors.initials: R
authors.lastname: De Bellis
authors.forename: G
authors.initials: G
authors.lastname: Ruiz-Argüelles
authors.forename: S
authors.initials: S
authors.lastname: Brandalise
authors.forename: E
authors.initials: E
authors.lastname: Jiménez-Fonseca
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction
chemical_list: D000903:Antibiotics, Antineoplastic; D003561:Cytarabine; C002205:zorubicin; D003630:Daunorubicin